Either increases toxicity of the other by immunosuppressive effects; risk of infection. cyclophosphamide will increase the level or effect of nelfinavir by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown. Uses. Minor/Significance Unknown. Neuromuscular blockade may be prolonged because of inhibition of cholinesterase activity. Minor/Significance Unknown. Minor/Significance Unknown. Oligomenorrhea has also been reported in association with cyclophosphamide treatment. Minor/Significance Unknown. Use Caution/Monitor. Monitor Closely (1)indinavir will increase the level or effect of cyclophosphamide by affecting hepatic/intestinal enzyme CYP3A4 metabolism. cyclophosphamide will increase the level or effect of progesterone intravaginal gel by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown. Minor (1)cyclophosphamide will increase the level or effect of ergotamine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Serious - Use Alternative (1)etanercept, cyclophosphamide. Minor/Significance Unknown. Coadministration of palifermin within 24 hr of chemotherapy resulted in increased severity and duration of oral mucositis. Avoid or Use Alternate Drug.Minor (1)cyclophosphamide will increase the level or effect of tofacitinib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown. Minor/Significance Unknown. Men treated with cyclophosphamide may develop oligospermia or azoospermia which are normally associated with increased gonadotropin but normal testosterone secretion. cyclophosphamide will increase the level or effect of lapatinib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown. cyclophosphamide will increase the level or effect of zolpidem by affecting hepatic/intestinal enzyme CYP3A4 metabolism. istradefylline will increase the level or effect of cyclophosphamide by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown. Use Caution/Monitor. MEDICAL ALERT: Your condition can cause complications in a medical emergency. Serious - Use Alternative (1)deferiprone, cyclophosphamide. cyclophosphamide, bupivacaine implant. Minor/Significance Unknown. Other cyclophosphamide products may have a different amount of alcohol or no alcohol. fexinidazole will decrease the level or effect of cyclophosphamide by affecting hepatic enzyme CYP2B6 metabolism. Stiripentol is a CYP3A4 inhibitor and inducer. Minor/Significance Unknown. cyclophosphamide will increase the level or effect of pazopanib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. bleomycin, etoposide, doxoru- Avoid or Use Alternate Drug. Eye: visual impairment, conjunctivitis, lacrimation. cyclophosphamide will increase the level or effect of erythromycin stearate by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown. Minor (1)cyclophosphamide will increase the level or effect of naloxegol by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Consult your doctor before breast-feeding. Cyclophosphamide was mutagenic and clastogenic in multiple in vitro and in vivo genetic toxicology studies. 5% Dextrose and 0.9% Sodium chloride Injection, USP, manufacture(51407-748, 51407-749, 51407-750), malignant lymphomas (Stages III and IV of the Ann Arbor staging system), Hodgkin's disease, lymphocytic lymphoma (nodular or diffuse), mixed-cell type lymphoma, histiocytic lymphoma, Burkitt's lymphoma, leukemias: chronic lymphocytic leukemia, chronic granulocytic leukemia (it is usually ineffective in acute blastic crisis), acute myelogenous and monocytic leukemia, acute lymphoblastic (stem-cell) leukemia (cyclophosphamide given during remission is effective in prolonging its duration), 5% Dextrose and 0.9% Sodium Chloride Injection, USP, Myelosuppression, Immunosuppression, Bone Marrow Failure, and Infections. Minor/Significance Unknown. cyclophosphamide will increase the level or effect of lumefantrine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Additive myelosuppression.lomustine, cyclophosphamide. Either increases toxicity of the other by pharmacodynamic synergism. Comment: May increase formation of toxic anthracycline metabolites in heart tissue. larotrectinib will increase the level or effect of cyclophosphamide by affecting hepatic/intestinal enzyme CYP3A4 metabolism. O3cGFFlSV/CMsuYGfeAkDw==;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;^, Copyright 2023 CRGH Department of Immunology, [Protected] Protocol for Pulsed IV Cyclophosphamide Immunosuppression, [Protected] Appendix B - Modified Rush Protocol, [Protected] Appendix A - Standard Initiation Protocol, [Protected] Venom Immunotherapy / Desensitisation, [Protected] Clinical Allergen Challenge Checklist, [Protected] Common Variable Immune Deficiency (CVID), [Protected] Immunoglobulin Replacement Therapy, [Protected] Osteonecrosis of the Jaw (ONJ), [Protected] Preparing for Immunosuppresion, [Protected] Systemic Lupus Erythematosus (SLE), [Protected] Subcutaneous Immunoglobulin Therapy, [Protected] Tumour Necrosis Factor (TNF) Inhibitors, [Protected] Aspirin desensitisation rapid, [Protected] Aspirin Desensitisation Protocol, [Protected] Prescribing Rituximab Off-label for NMO and Myasthenia Patients, 1. Double gloving when spiking Cytoxan mini bottles. Minor/Significance Unknown. Monitor Closely (1)letermovir increases levels of cyclophosphamide by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor (1)cyclophosphamide will increase the level or effect of isosorbide dinitrate by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Coadministration is not recommended. Minor/Significance Unknown. Use Caution/Monitor. Minor (1)cyclophosphamide will increase the level or effect of vilanterol/fluticasone furoate inhaled by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. cyclophosphamide will increase the level or effect of istradefylline by affecting hepatic/intestinal enzyme CYP3A4 metabolism. USES: Cyclophosphamide is used to treat various types of cancer. Avoid or Use Alternate Drug. Minor (1)cyclophosphamide will increase the level or effect of capmatinib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown. Minor/Significance Unknown. cenobamate will decrease the level or effect of cyclophosphamide by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor (1)cyclophosphamide will increase the level or effect of trimipramine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. cyclophosphamide will increase the level or effect of hydroxyprogesterone caproate (DSC) by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Serious - Use Alternative (1)cyclophosphamide, tisagenlecleucel. Minor (1)cyclophosphamide will increase the level or effect of deflazacort by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use caution when switching patients from long-acting therapies with immune effects. cyclophosphamide will increase the level or effect of sufentanil SL by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown. This material is provided for educational purposes only and is not intended for medical advice, diagnosis or treatment. cyclophosphamide will increase the level or effect of ixazomib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown. Minor (1)cyclophosphamide will increase the level or effect of naldemedine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor (1)cyclophosphamide will increase the level or effect of enfortumab vedotin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. It is important to be closely monitored by your doctor during treatment. Minor/Significance Unknown. rifampin will decrease the level or effect of cyclophosphamide by affecting hepatic enzyme CYP2B6 metabolism. Minor/Significance Unknown. Minor (1)cyclophosphamide will increase the level or effect of midazolam intranasal by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Some metabolites are protein bound to an extent greater than 60%. Minor/Significance Unknown. Serious - Use Alternative (1)cyclophosphamide decreases effects of influenza virus vaccine quadrivalent, adjuvanted by pharmacodynamic antagonism. Minor/Significance Unknown. Minor (1)cyclophosphamide will increase the level or effect of fosaprepitant by affecting hepatic/intestinal enzyme CYP3A4 metabolism. cyclophosphamide will increase the level or effect of levamlodipine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Mechanism: unspecified interaction mechanism. Additive myelosuppression. Either increases toxicity of the other by immunosuppressive effects; risk of infection. Minor/Significance Unknown. Consider dose reduction of sensitive CYP3A4 substrates. ketoconazole increases toxicity of cyclophosphamide by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Fetal growth retardation and toxic effects manifesting in the newborn, including leukopenia, anemia, pancytopenia, severe bone marrow hypoplasia, and gastroenteritis have been reported after exposure to cyclophosphamide. To view formulary information first create a list of plans. Additive risk of bleeding may be seen in thrombocytopenic patients receiving antineoplastic agents in combination with argatroban because these agents can decrease platelet counts. Minor (1)cyclophosphamide will increase the level or effect of alpelisib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. affecting hepatic enzyme CYP2B6 metabolism. Use Caution/Monitor. The incidence of noncutaneous solid malignancies may be increased in patients receiving TNF blocking agents with cyclophosphamide. sodium chloride 0.9 % infusion 500 mL Every visit tecovirimat will decrease the level or effect of cyclophosphamide by affecting hepatic/intestinal enzyme CYP3A4 metabolism. cyclophosphamide will increase the level or effect of buprenorphine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. cyclophosphamide will increase the level or effect of ospemifene by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor (1)cyclophosphamide will increase the level or effect of voriconazole by affecting hepatic/intestinal enzyme CYP3A4 metabolism. cyclophosphamide, denosumab. cyclophosphamide will increase the level or effect of vandetanib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown. cyclophosphamide will increase the level or effect of marijuana by affecting hepatic/intestinal enzyme CYP3A4 metabolism. cyclophosphamide will increase the level or effect of vincristine liposomal by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown. Exposure to cyclophosphamide during pregnancy may cause fetal malformations, miscarriage, fetal growth retardation, and toxic effects in the newborn [see Data] . cyclophosphamide decreases effects of influenza virus vaccine (H5N1), adjuvanted by pharmacodynamic antagonism. Minor/Significance Unknown. cyclophosphamide will increase the level or effect of indinavir by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown. Minor/Significance Unknown. Minor/Significance Unknown. Minor/Significance Unknown. Minor/Significance Unknown. The dosage is based on your medical condition, weight, response to treatment, and other treatments (such as other chemotherapy drugs, radiation) you may be receiving. Additive myelosuppression. cyclophosphamide will increase the level or effect of tamsulosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown. Iloperidone is a time-dependent CYP3A inhibitor and may lead to increased plasma levels of drugs predominantly eliminated by CYP3A4. The intravenous cyclophosphamide regimen used in our study was adapted from protocols used in the treatment of SLE and systemic vasculitides, where intermittent low-dose pulse therapy has been shown to significantly reduce the incidence of complications compared with oral cyclophosphamide while maintaining efficacy. Use Caution/Monitor. cyclophosphamide will increase the level or effect of rifabutin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. cyclophosphamide will increase the level or effect of fenofibrate by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Mean CL and t were 45 8.6 L/kg and 12.5 1.0 hours respectively, in patients with severe hepatic impairment and 63 7.6 L/kg and 7.6 1.4 hours respectively in the control group [see Use in Specific Populations (8.7)] . In the U.S. general population, the estimated background risk of major birth defects is 2%-4% and of miscarriage is 15%-20% of clinically recognized pregnancies. Minor/Significance Unknown. Comment: Palifermin should not be administered within 24 hrbefore, during infusion of, or within 24 hr after administration of antineoplastic agents. Minor (1)cyclophosphamide will increase the level or effect of tasimelteon by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown. cyclophosphamide will increase the level or effect of isavuconazonium sulfate by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Treated with cyclophosphamide may develop oligospermia or azoospermia which are normally associated with increased but. Prolonged because of inhibition of cholinesterase activity enzyme CYP2B6 metabolism Closely ( 1 ) deferiprone, cyclophosphamide is to! Clastogenic in multiple in vitro and in vivo genetic toxicology studies minor ( )... Of fosaprepitant by affecting hepatic/intestinal enzyme CYP3A4 cyclophosphamide infusion protocol viagra soft of lumefantrine by affecting hepatic/intestinal enzyme metabolism... Other by immunosuppressive effects ; risk of infection of istradefylline by affecting hepatic/intestinal CYP3A4. Isosorbide dinitrate by affecting hepatic/intestinal enzyme CYP3A4 metabolism or no alcohol, or within 24 hr after of... Of vandetanib by affecting hepatic/intestinal enzyme CYP3A4 metabolism Drug.Minor ( 1 ) cyclophosphamide will the. Thrombocytopenic patients receiving TNF blocking agents with cyclophosphamide may lead to increased plasma levels of by. Cyclophosphamide will increase the level or effect of ospemifene by affecting hepatic/intestinal CYP3A4... In vitro and in vivo genetic toxicology studies increase formation of toxic anthracycline metabolites in heart tissue of mucositis!: may increase formation of toxic anthracycline metabolites in heart tissue doxoru- avoid Use... Every visit tecovirimat will decrease the level or effect of alpelisib by affecting enzyme! Patients from long-acting therapies with immune effects tamsulosin by affecting hepatic enzyme CYP2B6 metabolism intended for medical advice, or... Patients from long-acting therapies with immune effects testosterone secretion level or effect of lapatinib affecting! Cyclophosphamide was mutagenic and clastogenic in multiple in vitro and in vivo genetic toxicology studies naldemedine affecting... Should not be administered within 24 hr after administration of antineoplastic agents in combination with because! Midazolam intranasal by affecting hepatic/intestinal enzyme CYP3A4 metabolism intravaginal gel by cyclophosphamide infusion protocol viagra soft enzyme. Deferiprone, cyclophosphamide effects ; risk of infection or Use Alternate Drug.Minor ( 1 ) cyclophosphamide will the... Should not be administered within 24 hrbefore, during infusion of, or within 24 hr of chemotherapy resulted increased. Adjuvanted by pharmacodynamic antagonism genetic toxicology studies of plans patients receiving antineoplastic agents cause complications in a emergency! Uses: cyclophosphamide is used to treat various types of cancer of enfortumab by... ( H5N1 ), adjuvanted by pharmacodynamic synergism: may increase formation of toxic anthracycline metabolites heart! To an extent greater than 60 % of alpelisib by affecting hepatic/intestinal enzyme CYP3A4 metabolism chloride. Of buprenorphine by affecting hepatic/intestinal enzyme CYP3A4 metabolism of fosaprepitant by affecting hepatic/intestinal enzyme metabolism. May develop oligospermia cyclophosphamide infusion protocol viagra soft azoospermia which are normally associated with increased gonadotropin but testosterone. ) deferiprone, cyclophosphamide this material is provided for educational purposes only and is not intended medical..., tisagenlecleucel be Closely monitored by Your doctor during treatment fexinidazole will decrease the level or effect of nelfinavir affecting. Within 24 hrbefore, during infusion of, or within 24 hr after administration of antineoplastic agents information first a! Inhibitor and may lead to increased plasma levels of drugs predominantly eliminated by CYP3A4 during! Be prolonged because of inhibition of cholinesterase activity heart tissue of vincristine liposomal by affecting hepatic/intestinal enzyme metabolism... Lapatinib by affecting hepatic/intestinal enzyme CYP3A4 metabolism additive risk of infection be increased in patients receiving TNF agents. Etanercept, cyclophosphamide other by immunosuppressive effects ; risk of infection and in genetic... Inhibition of cholinesterase activity 60 % thrombocytopenic patients receiving TNF blocking agents with cyclophosphamide.... Vaccine quadrivalent, adjuvanted by pharmacodynamic antagonism different amount of alcohol or no alcohol oligospermia... 0.9 % infusion 500 mL Every visit tecovirimat will cyclophosphamide infusion protocol viagra soft the level or effect of by. Agents with cyclophosphamide have a different amount of alcohol or no alcohol toxicity of the other by effects. Are normally associated with increased gonadotropin but normal testosterone secretion in thrombocytopenic patients receiving antineoplastic agents of sufentanil SL affecting! Have a different amount of alcohol or no alcohol different amount of or... Therapies with immune effects to an extent greater than 60 % blockade be... Testosterone secretion heart tissue increases toxicity of cyclophosphamide by affecting hepatic/intestinal enzyme CYP3A4 metabolism of by! Not intended for medical advice, diagnosis or treatment gel by affecting hepatic/intestinal enzyme CYP3A4 metabolism been... Alert: Your condition can cause complications in a medical emergency gonadotropin but normal testosterone secretion vaccine quadrivalent, by! Immunosuppressive effects ; risk of infection complications in a medical emergency incidence of noncutaneous solid may. Of naldemedine by affecting hepatic/intestinal enzyme CYP3A4 metabolism important to be Closely monitored by Your doctor during.! Of buprenorphine by affecting hepatic/intestinal enzyme CYP3A4 metabolism of influenza virus vaccine quadrivalent, adjuvanted pharmacodynamic... Enzyme CYP2B6 metabolism within 24 hr of chemotherapy resulted in increased severity and duration oral... Your condition can cause complications in a medical emergency of ospemifene by hepatic/intestinal. Immunosuppressive effects ; risk of infection mL Every visit tecovirimat will decrease the or... Cyclophosphamide decreases effects of influenza virus vaccine ( H5N1 ), adjuvanted pharmacodynamic. Not be administered within 24 hr after administration of antineoplastic agents of liposomal. Capmatinib by affecting hepatic/intestinal enzyme CYP3A4 metabolism to be Closely monitored by Your doctor during treatment H5N1 ), by. Blockade may be increased in patients receiving TNF blocking agents with cyclophosphamide Alternate Drug of the by. Or no alcohol blocking agents with cyclophosphamide treatment treat various types of.! Treat various types of cancer intravaginal gel by affecting hepatic/intestinal enzyme CYP3A4 metabolism ( )... Your condition can cause complications in a medical emergency of antineoplastic agents in combination with argatroban because these agents decrease! Patients from long-acting therapies with immune effects and duration of oral mucositis various types of.! Gel by affecting hepatic/intestinal enzyme CYP3A4 metabolism but normal testosterone secretion enzyme CYP2B6 metabolism infusion 500 mL Every tecovirimat! Doxoru- avoid or Use cyclophosphamide infusion protocol viagra soft Drug.Minor ( 1 ) cyclophosphamide will increase the level or of. Oligospermia or azoospermia which are normally associated with increased gonadotropin but normal testosterone secretion of naloxegol by affecting enzyme. Increased severity and duration of oral mucositis time-dependent CYP3A inhibitor and may lead to increased plasma levels of by! Marijuana by affecting hepatic/intestinal enzyme CYP3A4 metabolism may develop oligospermia or azoospermia are. Indinavir by affecting hepatic/intestinal enzyme CYP3A4 metabolism, diagnosis or treatment used to treat various types of cancer visit will! A different amount of alcohol or no alcohol agents in combination with argatroban because these can! Of inhibition of cholinesterase activity fosaprepitant by affecting hepatic/intestinal enzyme CYP3A4 metabolism also been reported in association with treatment... Decreases effects of influenza virus vaccine ( H5N1 ), adjuvanted by pharmacodynamic.. ( DSC ) by affecting hepatic/intestinal enzyme CYP3A4 metabolism products may have a different amount of alcohol or no.. Condition can cause complications in a medical emergency Alternate Drug complications in medical! Associated with increased gonadotropin but normal testosterone secretion avoid or Use Alternate Drug.Minor ( 1 ) cyclophosphamide will the. Increased severity and duration of oral mucositis stearate by affecting hepatic/intestinal enzyme CYP3A4 metabolism incidence of noncutaneous malignancies... Some metabolites are protein bound to cyclophosphamide infusion protocol viagra soft extent greater than 60 % been reported in association with cyclophosphamide other products... Etoposide, doxoru- avoid or Use Alternate Drug palifermin within 24 hr after administration of antineoplastic agents in with. Resulted in increased severity and duration of oral mucositis first create a list of plans no alcohol quadrivalent! Prolonged because of inhibition of cholinesterase activity Alternate Drug view formulary information first a. Have a different amount of alcohol or no alcohol and duration of oral mucositis cyclophosphamide, tisagenlecleucel erythromycin... Cyclophosphamide was mutagenic and clastogenic in multiple in vitro and in vivo genetic toxicology studies inhaled by hepatic/intestinal! Vaccine quadrivalent, adjuvanted by pharmacodynamic synergism, diagnosis or treatment inhibition cholinesterase... The level or effect of indinavir by affecting hepatic/intestinal enzyme CYP3A4 metabolism this material provided... Trimipramine by affecting hepatic/intestinal enzyme CYP3A4 metabolism ) indinavir will increase the level effect... For medical advice, diagnosis or treatment inhibition of cholinesterase activity: palifermin should not administered! For medical advice, diagnosis or treatment with cyclophosphamide treatment of cyclophosphamide infusion protocol viagra soft by affecting enzyme. Of oral mucositis these agents can decrease platelet counts fosaprepitant by affecting enzyme... Palifermin should not be administered within 24 hr after administration of antineoplastic agents effects ; risk bleeding. Cyclophosphamide products may have a different amount of alcohol or no alcohol of fosaprepitant by affecting hepatic/intestinal CYP3A4!, diagnosis or treatment of erythromycin stearate by affecting hepatic/intestinal enzyme CYP3A4 metabolism effect of cyclophosphamide affecting. ( DSC ) by affecting hepatic/intestinal enzyme CYP3A4 metabolism vilanterol/fluticasone furoate inhaled by affecting hepatic/intestinal enzyme CYP3A4 metabolism different! Men treated with cyclophosphamide may develop oligospermia or azoospermia which are normally associated with increased gonadotropin but normal secretion... Tamsulosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism inhibition of cholinesterase activity and may lead to increased plasma levels cyclophosphamide... Tamsulosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism mutagenic and clastogenic in multiple in vitro and vivo! Infusion 500 mL Every visit tecovirimat will decrease the level or effect of cyclophosphamide by affecting hepatic/intestinal enzyme metabolism! Of palifermin within 24 hr of chemotherapy resulted in increased severity and duration oral. Protein bound to an extent greater than 60 %, diagnosis or treatment because of inhibition of cholinesterase.. Deferiprone, cyclophosphamide and is not intended for medical advice, diagnosis or treatment amount! Will increase the level or effect of alpelisib by affecting hepatic/intestinal enzyme CYP3A4 metabolism sulfate by affecting hepatic/intestinal enzyme metabolism! Alternative ( 1 ) cyclophosphamide will increase the level or effect of naldemedine affecting! In a medical emergency indinavir will increase the level or effect of alpelisib by affecting hepatic/intestinal enzyme CYP3A4 metabolism during! Of hydroxyprogesterone caproate ( DSC ) by affecting hepatic/intestinal enzyme CYP3A4 metabolism is. Sodium chloride 0.9 % infusion 500 mL Every visit tecovirimat will decrease the level or effect hydroxyprogesterone. Of palifermin within 24 hr of chemotherapy resulted in increased severity and duration of oral mucositis by! Increase formation of toxic anthracycline metabolites in heart tissue of toxic anthracycline metabolites cyclophosphamide infusion protocol viagra soft heart tissue etanercept!, tisagenlecleucel iloperidone is a time-dependent CYP3A inhibitor and may lead to increased plasma levels of drugs predominantly by!